Based on our analysis of factors associated with immunotherapy receipt, both MMR status and disease stage at CRC diagnosis emerged as potential key factors in ICI-based treatment decision-making regardless of pre- or post-FDA approval. This evidence concerns the gene MRC1 and colorectal carcinoma.